• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypoalbuminemia and Posaconazole Therapeutic Drug Monitoring.

作者信息

Nix David E, Al-Obaidi Mohanad, Zangeneh Tirdad

机构信息

Pharmacy Practice & Science, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, USA.

Division of Infectious Diseases, The University of Arizona, Tucson, Arizona, USA.

出版信息

Open Forum Infect Dis. 2024 Aug 9;11(8):ofae452. doi: 10.1093/ofid/ofae452. eCollection 2024 Aug.

DOI:10.1093/ofid/ofae452
PMID:39205926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11350285/
Abstract
摘要

相似文献

1
Hypoalbuminemia and Posaconazole Therapeutic Drug Monitoring.低白蛋白血症与泊沙康唑治疗药物监测
Open Forum Infect Dis. 2024 Aug 9;11(8):ofae452. doi: 10.1093/ofid/ofae452. eCollection 2024 Aug.
2
Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.血液病恶性肿瘤患者应用泊沙康唑片剂和口服混悬液进行抗真菌预防：治疗药物监测、疗效和治疗浓度不理想的相关因素。
Mycoses. 2020 Jan;63(1):89-94. doi: 10.1111/myc.13020. Epub 2019 Nov 20.
3
Real-world Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels.泊沙康唑在肿瘤患者中治疗药物监测的真实世界经验：低白蛋白血症作为泊沙康唑治疗水平不足预测指标的临床意义
Open Forum Infect Dis. 2024 Mar 29;11(5):ofae185. doi: 10.1093/ofid/ofae185. eCollection 2024 May.
4
Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance.使用高剂量泊沙康唑片未能达到治疗水平，可能是由于清除率提高所致。
J Oncol Pharm Pract. 2018 Jan;24(1):63-66. doi: 10.1177/1078155216673228. Epub 2016 Oct 18.
5
Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India.与口服泊沙康唑片治疗剂量不足相关的因素：来自印度一家三级护理中心的详细分析。
Int J Infect Dis. 2022 Nov;124:76-80. doi: 10.1016/j.ijid.2022.09.004. Epub 2022 Sep 9.
6
Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.伏立康唑和泊沙康唑的治疗药物监测：一项回顾性研究。
Ann Clin Microbiol Antimicrob. 2017 Sep 11;16(1):60. doi: 10.1186/s12941-017-0235-8.
7
Progress of triazole antifungal agent posaconazole in individualized therapy.三唑类抗真菌药泊沙康唑个体化治疗的研究进展
J Clin Pharm Ther. 2022 Dec;47(12):1966-1981. doi: 10.1111/jcpt.13821. Epub 2022 Dec 3.
8
Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.泊沙康唑治疗药物监测的真实世界研究：单中心经验和文献复习。
Pharmacotherapy. 2013 Oct;33(10):1117-25. doi: 10.1002/phar.1328. Epub 2013 Jul 17.
9
Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.临床实践中的泊沙康唑治疗药物监测及常规实验室检测指标对泊沙康唑血药浓度影响的纵向分析。
Mycoses. 2019 Aug;62(8):698-705. doi: 10.1111/myc.12948. Epub 2019 Jun 18.
10
A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring.泊沙康唑静脉给药治疗肝肾功能损害患者侵袭性土曲霉感染的病例报告：治疗药物监测的安全性及作用
BMC Pharmacol Toxicol. 2017 Jan 31;18(1):8. doi: 10.1186/s40360-017-0115-z.

引用本文的文献

1
Effect of hypoalbuminemia on drug pharmacokinetics.低白蛋白血症对药物药代动力学的影响。
Front Pharmacol. 2025 Feb 20;16:1546465. doi: 10.3389/fphar.2025.1546465. eCollection 2025.

本文引用的文献

1
Real-world Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels.泊沙康唑在肿瘤患者中治疗药物监测的真实世界经验：低白蛋白血症作为泊沙康唑治疗水平不足预测指标的临床意义
Open Forum Infect Dis. 2024 Mar 29;11(5):ofae185. doi: 10.1093/ofid/ofae185. eCollection 2024 May.
2
Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: Endorsed by the Mycoses Study Group Education and Research Consortium.三唑类抗真菌治疗药物监测的应用：来自感染病学会药师协会的观点：得到了真菌病研究组教育与研究联合会的认可。
Pharmacotherapy. 2023 Oct;43(10):1043-1050. doi: 10.1002/phar.2850. Epub 2023 Aug 14.
3
Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades.低蛋白血症与药代动力学：当对一个基本概念的误解导致数十年反复出现错误时。
Antibiotics (Basel). 2023 Mar 4;12(3):515. doi: 10.3390/antibiotics12030515.
4
Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.泊沙康唑在实验性侵袭性肺曲霉病中的药效学：血清半乳甘露聚糖作为抗真菌疗效的动态终点的实用性。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01574-20.
5
Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.成人危重症患者静脉注射泊沙康唑的总浓度和游离浓度的群体药代动力学。
Crit Care. 2019 Jun 6;23(1):205. doi: 10.1186/s13054-019-2483-9.
6
Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.临床实践中的泊沙康唑治疗药物监测及常规实验室检测指标对泊沙康唑血药浓度影响的纵向分析。
Mycoses. 2019 Aug;62(8):698-705. doi: 10.1111/myc.12948. Epub 2019 Jun 18.
7
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.泊沙康唑在侵袭性肺曲霉病和毛霉病中性粒细胞减少小鼠模型中的比较药效学。
Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.
8
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.泊沙康唑对烟曲霉野生型和 Cyp51 突变株在侵袭性肺曲霉病体内模型中的药效学靶标测定。
Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.
9
Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.泊沙康唑在人血清中的药效作用大于非蛋白结合血清浓度所预测的。
Antimicrob Agents Chemother. 2011 Jul;55(7):3099-104. doi: 10.1128/AAC.01671-10. Epub 2011 Apr 18.
10
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.泊沙康唑治疗侵袭性肺曲霉病的药代动力学和药效学：抗真菌治疗的临床意义。
J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28.